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Abstract: The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including 
  non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-
targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the EGFR TKIs, is currently 
FDA approved in second and third line therapy. However, recent studies showed that erlotinib is also effective as maintenance therapy 
after initial chemotherapy, improving disease free survival and possibly overall survival. Our current understanding of erlotinib’s mech-
anism of action, with the discovery that EGFR mutation confers higher response rate, has propelled this agent into the first line setting. 
Advances in molecular testing and clinical research of this agent and other agents in this class will eventually change the way we utilize 
EGFR TKIs in the near future.
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“Time is the measurer of all things, but is itself immeasurable, and the grand discloser of all things, but is itself undisclosed.”
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Introduction
Life is unexpectedly abbreviated for patients newly 
diagnosed  with  advanced  lung  cancer.  Despite  an 
impressive national anti-tobacco campaign and excit-
ing new targeted therapies, lung cancer remains the 
leading cause of cancer mortality among men and 
women in the United States, with non-small-cell lung 
cancer  (NSCLC)  accounting  for  the  vast  majority 
of lung cancer cases. In 2012, the American Cancer 
Society  estimates  226,160  new  cases  of  lung  can-
cer in the United States. The prognosis of this dis-
ease  is  dismal,  with  an  astonishing  70%  (160,340 
patients) of those newly diagnosed dying within the 
first year.1 This means 439 deaths a day, and in the 
twenty minutes it takes the reader to finish review-
ing this manuscript, another 5 patients will have died 
of lung cancer. Even though the number of deaths in 
lung cancer exceeds the number of deaths of breast, 
colon and prostate cancer combined, the funding for 
lung cancer research is far behind the amount poured 
into these other cancers. The National Lung Cancer 
Partnership estimates that $37,616 research dollar per 
death is directed towards breast, colorectal and pros-
tate cancer research combined. In contrast, lung can-
cer receives $1,675 research dollar per death.2
Most patients with NSCLC are diagnosed at an 
advanced stage of disease, and therefore, treatment 
goal is usually palliative in nature. In patients with 
advanced stage NSCLC and with good performance 
status (Eastern Cooperative Oncology Group perfor-
mance status 0 or 1), the standard of care involves 
four to six cycles of a platinum-based double-agent 
regimen  which  has  shown  to  extend  overall  sur-
vival (OS) to a median of 10 to 13 months, reduce 
disease-related  symptoms,  and  improve  quality  of 
life.3–6  Three  of  five  patients  with  advanced  stage 
NSCLC  will  have  disease  control  at  eight  weeks 
with  platinum-based  regimens.7  Despite  numerous 
randomized  trials  comparing  different  combination 
chemotherapy  regimens,  no  doublet  regimen  has 
proven to be superior. Several clinical studies inves-
tigated the role of extending platinum-based chemo-
therapy beyond the four cycles in those with stable 
disease, but they revealed similar survival and more 
toxicity in the extended duration of platinum-based 
therapy.8–12 Current standard of care is a finite number 
of chemotherapy treatments, despite the fact that the 
disease will invariably progress in the future. Due to 
this bleak outcome, a strategy other than extending 
platinum-based chemotherapy is desirable, in hopes 
of continued overall survival benefit and a reduction 
in disease-related symptoms, while maintaining a sat-
isfactory quality of life.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Epidermal  growth  factor  receptor  tyrosine  kinase 
inhibitors (EGFR TKIs) were first studied in recur-
rent lung cancer patients in the 1990s. The first com-
pound studied, gefitinib, showed therapeutic activity 
in phase II trials with patients with recurrent advanced 
non-small cell lung cancer.13 Although gefitinib has 
subsequently been withdrawn from the United States 
market due to lack of efficacy in the phase III ISEL 
trial,14  there  were  anecdotal  reports  of  dramatic 
response with gefitinib. Clearly not all patients ben-
efited from this agent, but patients with certain clini-
cal  characteristics  were  identified  as  predictive  of 
response; these included female gender, adenocarci-
noma histology, Asian ancestry and non-smokers.15 
This was also observed in the BR 21 trial16 using erlo-
tinib, which eventually led to approval of this agent 
in recurrent lung cancer in 2004. The exact mecha-
nism of action of the EGFR TKIs was later elucidated 
by Lynch and Paez, describing a specific mutation in 
the EGFR tyrosine binding site.17,18 (Fig. 1) EGFR is 
critical in many cell-signaling pathways that influ-
ence nuclear gene activation, cell division, apoptosis, 
motility and adhesion; when EGFR is overexpressed, 
as is the case in many tumor types,19 tumorigenesis 
and tumor growth are accelerated. Competing with 
adenosine  triphosphate,  erlotinib  hydrochloride, 
reversibly binds to the intracellular catalytic domain 
of epidermal growth factor receptor (EGFR) tyrosine 
kinase, thereby inhibiting phosphorylation and block-
ing the signal transduction events and tumorigenic 
effects associated with EGFR activation.
Erlotinib is orally administered and is about 60% 
absorbed,  but  its  bioavailability  is  substantially 
increased by food to almost 100%, as the solubil-
ity is pH dependent. Peak plasma levels occur four 
hours after dosing, and the plasma level is reduced 
by cigarette smoking.20 Therefore, erlotinib would be 
theoretically less effective in smokers due to lower 
serum levels. Erlotinib is metabolized predominantly 
by CYP3A4; therefore, inhibitors of CYP3A4 would eGFR TKI maintenance therapy in lung cancer
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be expected to increase drug exposure and conversely 
CYP3A4  inducers  would  be  expected  to  decrease 
efficacy. Approximately 80% of the drug is excreted 
in the feces, and its use should be used with extra cau-
tion in patients with a total bilirubin greater than three 
times the upper limit of normal.21
The side effect profile of the EGFR TKIs is much 
more tolerable than traditional chemotherapy agents. 
In  the  past,  conventional  cytotoxic  chemotherapy 
was  given  for  a  limited  number  of  cycles  mainly 
due  to  increased  toxicities  and  limited  therapeutic 
advantage.22 This is not the case with EGFR TKIs. 
In fact, grade 3 and 4 toxicities most often attributed 
to these drugs are rash and diarrhea, rarely the cause 
of discontinuation of therapy. In summary, erlotinib 
is orally available, generally well-tolerated, and has 
less impact on the quality of life.23
Clinical Studies and Efficacy
The concept of using erlotinib as maintenance ther-
apy in NSCLC was a logical step, as it has shown an 
improvement in survival, delayed disease progression 
and delayed worsening of disease-related symptoms 
in  the  advanced  NSCLC  setting  after  progressing 
with  previous  chemotherapy.16  This  new  class  of 
agents has been investigated as maintenance therapy 
using two approaches (Table 1): immediate sequen-
tial therapy (IST) and prolonged response-dependent 
therapy (PRT) (Fig. 2). The IST approach consists of 
using an EGFR TKI immediately after completion 
of standard induction chemotherapy if the disease is 
stable or responding to initial chemotherapy. IST is 
based on the historic tumor growth model proposed 
by Goldie and Coldman,24 in which sequential use of 
different agents could potentially evade the develop-
ment of resistance in cancer cells. The PRT approach 
uses an EGFR TKI as front line therapy in conjunc-
tion with chemotherapy. If there is stable disease or 
response to the initial combination of an EGFR TKI 
with chemotherapy, the EGFR TKI is continued alone 
until disease progression.
Several  studies  have  been  done  using  these 
approaches  and  we  will  review  them  in  detail. 
Although the INTACT 1,25 INTACT 2,26 TRIBUTE27 
and  the  TALENT  trials28  did  not  show  any  over-
all  survival  benefit  with  the  addition  of  an  EGFR 
TKI  to    platinum-based  doublet  regimens  then  fol-
lowed  by  maintenance  therapy  in  patients  with 
  chemotherapy-naïve  advanced  NSCLC,  a  subset 
analysis of the TRIBUTE trial showed that patients 
treated with erlotinib for more than 150 days showed 
an  increased  response  duration,  strengthening  the 
suggestion  of  erlotinib  in  the  maintenance  setting. 
Similarly, in the INTACT 2 trial, patients with adeno-
carcinoma that received more than 90 days of 500 mg 
or 250 mg of gefitinib with chemotherapy followed 
by gefitinib at respective doses, had a longer median 
survival compared with patients treated with chemo-
therapy alone, 16 and 17 m vs. 13.9 m respectively.
Two trials evaluating immediate sequential ther-
apy have shown a statistically significant improve-
ment in OS, one involving an EGFR TKI.29 Ciuleanu 
and colleagues investigated maintenance pemetrexed 
versus placebo in patients who had completed four 
cycles of platinum-based double-agent chemotherapy 
without evidence of disease progression.29 Similar to 
Ciuleanu’s trial methods above, the SATURN trial 
investigated maintenance erlotinib 150 mg/day com-
pared with placebo in patients without disease pro-
gression  after  four  cycles  of  a  platinum-doublet.30 
Co-primary end-points were evaluated: Progression 
Free Survival (PFS) in the intent-to-treat patient pop-
ulation and PFS in the subset of patients with EGFR 
protein  overexpression  by  immunohistochemistry, 
defined  as  .10%.  1949  patients  received  induc-
tion  platinum-based  chemotherapy  at  the  discre-
tion  of  individual  investigators  (bevacizumab  and 
pemetrexed were not permitted as the non-platinum 
agent); of the 45% of patients who had disease con-
trol after four cycles, 438 patients were randomized 
to erlotinib and 451 patients to   placebo. Differences 
in PFS and OS (although a   secondary endpoint) were 
in favor or erlotinib. The median PFS was 12.3 weeks 
for erlotinib compared to 11.1 weeks for placebo (HR 
0.71,  P  ,  0.0001)  and  overall  survival  showed  a 
one-month survival advantage, 12 months compared 
to 11 months respectively (HR 0.81, P = 0.0088). 
  Quality of life was also assessed using the validated 
Functional Assessment of Cancer Therapy—Lung,31 
and there was no significant difference for time to 
deterioration in quality of life for patients receiving 
erlotinib compared to placebo. This study led to the 
approval of erlotinib in April 2010 as first-line main-
tenance therapy for patients with locally advanced or 
metastatic NSCLC who had not progressed after initial 
platinum-based chemotherapy. Currently,   erlotinib is Huang and Powers
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the only EGFR TKI approved by the US FDA for use 
in patients with NSCLC.
Since  the  introduction  of  bevacizumab  in  the 
initial therapy for non-small cell lung cancer, the 
ATLAS trial32 sought to elucidate the efficacy of erlo-
tinib with bevacizumab as IST. The study enrolled 
patients  without  disease  progression  after  initial 
platinum-based  therapy  with  bevacizumab  and 
compared maintenance therapy with bevacizumab 
and erlotinib versus bevacizumab and   placebo. The 
study  met  its  primary  endpoint  after  the  second 
interim analysis showing improvement of PFS with 
the combination regimen versus bevacizumab alone 
(4.76 months compared to 3.71 months; HR = 0.71, 
P = 0.0006). However, the overall survival was not 
statistically  different. A  three-arm  phase  III  trial 
investigating the role of maintenance gemcitabine 
or erlotinib compared with observation after ini-
tial  therapy  with  cisplatin-gemcitabine  looked  at 
PFS as the primary endpoint.33 Patients in both the 
gemcitabine arm and erlotinib arm experienced sig-
nificantly  longer  progression-free  survival  when 
compared to the observation arm. Although gemcit-
abine and erlotinib were not compared head-to-head, 
median PFS was 3.8 months for the   gemcitabine 
arm (n = 155 patients) and 2.9 months for the erlo-
tinib arm (n = 155 patients). The data set is not 
mature yet, but no significant difference in overall 
survival has been observed at interim   analyses. A 
pooled analysis of these 3 trials confirmed the ben-
efit of maintenance therapy with EGFR TKI with 
improvement in OS (HR = 0.87; P = 0.003), and 
PFS (HR 0.76 ; P , 0.00001), All patients benefited 
from the therapy especially in the group of women 
non-smokers,  non-squamous  histology,  PS  0  and 
patients who did not progress after 4 cycles of ini-
tial therapy.34
Discussion
Despite  the  disadvantage  in  research  funding  and 
less-than-robust grass-root movement for awareness 
of lung cancer in the community, there have been 
small yet significant advancements in the field of lung 
cancer therapy. The use of EGFR TKIs in NSCLC 
has proved beneficial in a variety of settings, yet this 
drug is just the beginning of a new wave of targeted 
therapies. The EGFR TKI is currently used routinely 
in the management of advanced lung cancer, but the 
setting of its use is in flux at the present time with 
several undefined issues.
Epidermal growth factor
Epidermal growth factor receptor
Cell cycle regulation
cell proliferation
angiogenesis
Inhibition of apoptosis
Increased survival
Tyrosine kinase domain
Figure 1. Representation of epidermal Growth Factor Receptor in the surface of the cell and its biological effect on cellular processes. The tyrosine kinase 
domain represented in red is the target of eGFR TKI is located in the intracellular portion of the receptor and it is responsible for activation and phospho-
rylation of intracellular proteins. Adapted from Baselga J. Cancer Cell. 2002;2:93–5.Huang and Powers
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The first issue is the timing in the use of erlotinib, 
especially in patients that harbors EGFR mutation. As 
early as 2006, phase II trials have looked into erlo-
tinib as frontline therapy in advanced NSCLC,35 even 
studying it exclusively in the elderly population over 
70 years old.36 The IPASS study was the first study to 
show the benefit of this class of drugs as a first line 
agent compared with chemotherapy in a population 
with favorable clinical characteristics as mentioned 
above. The study showed improved PFS in the subset 
of patients harboring an EGFR mutation.37
The next issue involves the expression of EGFR 
mutations.  EGFR  mutations  are  most  commonly 
located on exon 19 or exon 21. The incidence of EGFR 
mutations in NSCLC varies from as low as 8% to as 
high as 66% of patients, depending on how the muta-
tions are analyzed, geographical location, as Asia has 
higher frequency of mutations than North America, 
and other clinical characteristics.38,39 Namely, EGFR 
mutations  occur  more  frequently  in  females  than 
males, are almost exclusively found in patients with 
adenocarcinoma  histology  (and  nearly  two  times 
more  likely  in  well-to  moderately-  differentiated 
  adenocarcinomas  than  in    poorly-  differentiated 
  adenocarcinomas), and are much more frequent in 
never-smokers than ever-smokers.40,41 There appears 
to be an inverse correlation between smoke exposure 
and EGFR mutation, with higher amount of smoke 
exposure  having  lower  incidence  of  EGFR  muta-
tion.37,40  Not  only  does  the  EGFR  mutation  occur 
less often in smokers, but erlotinib is less effective 
in smokers due to lower serum levels as well. EGFR 
mutations do not seem to be associated with the age 
of the patient or stage of the lung cancer.39 In 2004, 
when the FDA came out with their report on the afore-
mentioned gefitinib, the exact same clinical charac-
teristics were thought to be predictive of response to 
EGFR TKIs prior to the knowledge about of EGFR 
mutation.15 The reason can now be explained; the 
patients with these clinical characteristics are most 
likely  to  harbor  an  EGFR  mutation,  who  in  turn 
respond best to EGFR TKIs.
Subsequent studies in Japan by Mitsudomi et al42 
and Maemondo et al43 done exclusively in patients 
with EGFR mutation confirmed the improvement in 
response and PFS in patients with EGFR mutation 
Chemotherapy
Maintenance approach
Until disease
progression
Until disease
progression
EGFR TKI
Immediate Sequential Therapy (IST)
Prolonged Response Dependent Therapy (PRT)
EGFR TKI
Stable or responding disease
Stable or responding disease
Chemotherapy
Figure 2. Two different approaches for maintenance therapy using eGFR TKIs. Immediate sequential therapy (IST) uses an eGFR TKI immediately after 
completion of standard induction chemotherapy if the disease is stable or responding to initial chemotherapy. The prolonged response dependent therapy 
(PRT) approach utilizes the EGFR TKI in first line therapy in conjunction with chemotherapy. If there is stable disease or response to the initial combination 
of an eGFR TKI with chemotherapy, the eGFR TKI is continued until disease progression.eGFR TKI maintenance therapy in lung cancer
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using gefitinib as first line therapy compared with 
chemotherapy. The  OPTIMAL  study,38  a  phase  III 
trial,  showed  similar  benefit  using  erlotinib  in  the 
first line setting. No trial has yet to show a statisti-
cally significant median overall survival benefit in the 
first line setting, although the Maemondo et al trial 
showed  a  7  month  survival  advantage42 ( Table  2). 
As EGFR testing becomes more routine in clinical 
practice, erlotinib and other EGFR TKIs may soon 
become one of the standard agents used in first-line 
therapy for patients with EGFR mutation. In the near 
future,  it  would  be  plausible  to  see  another  FDA-
  approved indication for EGFR TKIs as first line ther-
apy in NSCLC. This would alter the concept of IST 
maintenance after chemotherapy.
The  third  issue  is  the  testing  of  tumors  for  the 
genetic  mutation.  Testing  for  mutations  in  EGFR, 
overexpression  of  EGFR  protein  levels  via  immu-
nohistochemistry or an increase in gene copy num-
bers via fluorescence in-situ hybridization requires 
a non-neglible amount of tumor, which can be prob-
lematic when the majority of patients diagnosed with 
lung cancer had a fine needle aspiration or bronchos-
copy washing. With the availability of an increas-
ing number of specific molecularly-targeted agents, 
the acquisition of a predetermined amount of fresh 
tumor tissue for testing at time of initial diagnosis 
may become standard of care. Currently, the EGFR 
mutation analysis is the gold standard to determine 
if patients are likely to respond to erlotinib. As dis-
cussed previously, this is a time consuming method 
and it may not be available in patients with subop-
timal tissue sampling. Other methods are currently 
available and others in the horizon will soon solve the 
dilemma of the need of additional biopsy in order to 
obtain tissue for testing.
Promising,  cost-effective,  and  easy  to  sample, 
the matrix-assisted laser desorption/ionization time-
of-flight  (MALDI-TOF)  mass  spectrometry  plasma 
proteomic signature (VeriStrat®)44 appears to be able 
to  predict  those  who  will  have  improved  PFS  and 
OS with EGFR TKI therapy alone,45 or in combina-
tion  with  the  VEGF  inhibitor,  bevacizumab.46  The 
results seem independent of histology, gender, ethnic-
ity, smoking status, and other biomarkers like EGFR 
and K-ras. Carbone et al tested the serum from 441 
of  the  731  original  patients  from  the  BR.21  trial16 
and classified patients into VeriStrat Good (VSGood) 
Table 2. First line therapy using eGFR TKIs vs. conventional chemotherapy in patients with advanced NSCLC.
Trial Inclusion criteria Therapy arms no of  
patients
Median  
overall  
survival
Overall  
response
Median  
time to  
progression
Mok et al,  
“IPASS”37 
(Phase III)
Asian 
Age . 18 
Adenocarcinoma or  
bronchioloalveolar  
carcinoma 
Non-smoker or  
former light smoker 
wHO PS 0–2
Gefitinib 
vs. 
Carboplatin + paclitaxel  
for up to 6 cycles
609 
132* 
91** 
vs. 
608 
129* 
85**
18.8 m 
21.6 m* 
11.2 m** 
vs. 
17.4 m 
21.9 m* 
12.7 m**
43% 
71.2%* 
1.1%** 
vs. 
32.2% 
47.3%* 
23.5%**
5.7 m 
9.6 m* 
1.6 m** 
vs. 
5.8 m 
6.3 m* 
5.5 m**
Mitsudomi  
et al42 
(Phase III)
Age # 75 
eGFR mutation + 
Included pts with  
post-op recurrent  
disease 
wHO PS 0–1
Gefitinib 
vs. 
Cisplatin + docetaxel  
every 21 days for  
3–6 cycles
86 
vs. 
86
Not reported 62.1% 
vs. 
32.2%
9.2 m 
vs. 
6.3 m
Maemondo  
et al43 
(Phase III)
Age , 75 
eGFR mutation + 
eCOG PS 0–2
Gefitinib 
vs. 
Carboplatin + paclitaxel  
for 3–6 cycles
114 
vs. 
114
30.5 m 
vs. 
23.6 m
73.7% 
vs. 
30.7%
10.8 m 
vs. 
5.4 m
Zhou et al,  
“OPTIMAL”39 
(Phase III)
Age . 18 
eGFR mutation + 
eCOG PS 0–2
erlotinib 
vs. 
Carboplatin + gemcitabine  
for up to 6 cycles
82 
vs. 
72
Not reported 83% 
vs. 
36%
13.1 m 
vs. 
4.6 m
notes: *Presence of eGFR mutation; **negative for eGFR mutation.Huang and Powers
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or  VeriStrat  Poor  (VSPoor),  with  only  1%  being 
  indeterminately classified.47 In the 292 of 441 patients 
who  received  erlotinib  therapy  in  the  second-  or 
third-line setting, this test was predictive of disease 
control  rate  (VSGood:  68.2%  vs.  VSPoor:  30.5%; 
P = 0.0001) and objective response rate (VSGood: 
11.5% vs. VSPoor: 1.0%; P = 0.002). Those patients 
classified as VSGood who received erlotinib (n = 183 
patients) had a median overall survival of 10.5 months 
compared to the 4.0 month median overall survival 
in the remaining 109 patients who received erlotinib 
yet were classified as VSPoor. This was statistically 
significant,  with  a  hazard  ratio  of  0.37  (95%  CI: 
0.28–0.48; P , 0.0001) favouring the erlotinib arm. 
A subsequent study showed that this test can also be 
used when erlotinib is combined with bevacizumab.45 
The median OS was 61 weeks in the group classi-
fied as “good” compared to 24 weeks in the “poor” 
group, and median PFS was 36 weeks compared to 
8 weeks, respectively. Most recently, Lazzari and col-
leagues looked into the plasma proteomic profiles of 
111 NSCLC patients at baseline, during the course of 
EGFR TKI therapy and at treatment withdrawal.48 At 
baseline, a “good” classification by   VeriStrat, when 
compared with those classified as “poor”, correlated 
with longer PFS (HR 0.54, P = 0.005) and OS (HR 0.4, 
P , 0.0001), correlating with previous studies. About 
one-third of those classified as “good” at baseline had 
changed to “poor” predictive value at the time of treat-
ment  withdrawal,  associated  with  the  development 
of new cancerous lesions, suggesting its utility not 
only in treatment selection but possibly in treatment 
monitoring  as  well.  Despite  these  positive  studies, 
  Taguchi et al43 showed that VeriStrat does not appear 
to be prognostic for NSCLC patients not treated with 
EGFR TKI therapy, looking at three control groups 
from Italy, Vanderbilt and Poland; there was no statis-
tically significant difference in risk of death between 
VSGood and VSPoor groups. These studies show that 
VeriStrat could be a valuable tool to predict response 
to therapy. As it is currently available, VeriStrat could 
alter the decision making in the use of erlotinib.
Detection of EGFR mutation in circulating lung 
cancer  tumor  cells  is  a  feasible  technique  demon-
strated in a study published in 2008.49 Similar to the 
studies testing for the EGFR mutation in the tumor,37–40 
the patients with positive EGFR mutation detected 
in  their  circulating  tumor  cells  showed  improved 
  outcome. If this is a concept that can be proven in a 
large scale study, the need for biopsy of the tumor for 
testing may became obsolete, eliminating the risks 
associated with these procedures.
The  presence  of  a  different  mutation  involving 
K-ras seems to confer decreased activity with EGFR 
TKIs.50 This leads into another important question: 
is it still rational to use erlotinib in patients with-
out knowledge of the EGFR expression/mutation or 
K-ras pathway? Due to the reliance on an adequate 
tissue sample, better predictive tools will guide and 
optimize future treatment strategies in NSCLC.
Ongoing studies are hoping to answer questions 
regarding the use of erlotinib in maintenance therapy 
for advanced NSCLC. Currently a study being con-
ducted by Roche (NCT01328951) is investigating the 
role of IST with erlotinib versus erlotinib at time of 
progression. The primary endpoint is overall survival 
outcome  and  this  study  interestingly  excludes  all 
patients that harbor EGFR mutation. Another study 
is  investigating  the  combination  of  erlotinib  with 
OSI-906 (a IGF-1R, insulin growth factor-1 receptor 
tyrosine kinase inhibitor) versus erlotinib with pla-
cebo in patients with non-progressive disease after 
four cycles of platinum-based induction chemother-
apy (NCT01186861) for advanced NSCLC.
Several new EGFR tyrosine kinase inhibitor like Lap-
atinib, BIBW 2992, and others are currently in clinical 
trials. If proven effective, they will be added to the num-
ber of agents currently available to treat lung cancer.
In  conclusion,  erlotinib  is  a  well-tolerated  oral 
EGFR TKI that currently has a role in maintenance 
therapy in NSCLC. Its use in lung cancer is already 
widely accepted, but our knowledge regarding when 
to use and in what circumstances will likely shift in the 
near future. The availability of more accessible tech-
niques for mutational testing of EGFR and K-ras as 
well as improvement of laboratory testing will allow 
us to select the patient population that will benefit the 
most from these agents. This pharmaco-genetic selec-
tion will undoubtedly move us closer to the personal-
ized medicine that the oncology field has set out to 
achieve since its inception, and that our patients have 
pleaded and hoped for decades.
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